
The 10 best FSA-approved foot massagers, according to podiatrists
'Foot massagers are a great way to soothe tired, achy feet and FSA-approved massagers have the added bonus of potentially saving people some of the expense,' says Dr. Michael Nirenberg, a clinical and forensic podiatrist at Friendly Foot Care in Indiana. 'I have seen both FSA and non-FSA foot massagers that are excellent. My feeling is that health care is expensive, and if you can save a little money, go for an FSA-approved foot massager.'
From FSA-approved foot massagers that help boost circulation and eradicate everyday pains to options that simply melt away stress and promote relaxation, here's exactly what to look for and which options to shop for some extra pep in your step.
Caresky Pro Shiatsu Foot Massager
Between its three heat levels, safety timer, numerous massage modes and remote control for ultimate convenience, this FSA-approved foot massager checks off every box. 'I recommend the Caresky Pro Foot Massager,' says Nirenberg says. 'This massager gives a good balance between features and safety. It offers multiple types of massage and heat, and while at first glance it looks bulky, it is not heavy.' The best part? It comfortably fits feet up to size 14.
TheraFlow Small Dual-Foot Massager
If staying pain-free on the road is a priority for you, be sure to grab this compact, expert-approved pick that doesn't require any batteries or charging ports to operate. 'This is a portable, manual option that is great for targeting plantar fasciitis pain and improving circulation,' says Dr. Gregory Alvarez, podiatrist at Ankle & Foot Centers of America.
Cloud Massage Shiatsu Foot Massager
To feel like you're walking on clouds, consider adding this comfortable option to your cart. 'This one offers deep-tissue massage, heat and compression therapy, making it suitable for chronic foot pain and swelling,' Alvarez says.
Bob and Brad Foot Massager
The allure of this FSA-approved foot massager is that it's designed to feel like a lifelike massage that uses hands and fingers to melt away pain and sensitivity. Its remote control further adds to its convenience, while multiple massage modes, heat settings and intensities allow you to walk away feeling lighter and more comfortable in your step.
Renpho Shiatsu Foot Massager With Heat
Alvarez recommends this popular model because 'it combines kneading, rolling and heat functions in a compact design, ideal for stress relief and circulation.' As it focuses predominantly on massaging the arches and heel of the foot — as opposed to the toes — it makes for a solid option for those struggling with plantar fasciitis.
Miko Shiatsu Foot, Calf and Ankle Massager With Heat
Whether you're experiencing swelling, neuropathy or chronic pain, this foot massager with access to your calves provides some much-needed relief with your choice of intensity. 'This massager offers many different options and massage levels for those with sensitive feet,' Nirenberg says. Plus, the included remote allows you to personalize your foot massage, well, remotely.
Tisscare Foot Massager With Heat
This FSA-eligible foot massager combines heat therapy with shiatsu massage to deliver a spa-grade therapeutic experience from the comfort of your favorite chair. It's equipped with five levels of air compression and three massage modes to melt away sore spots. Use the adjustable handle to angle it toward either your feet or your calves for a bespoke massage experience to promote circulation where you need it most.
Tadoune 2-in-1 EMS Foot Massager Mat
For ultimate relief on the go, look no further than this 2-in-1 foot massager mat that doubles as a back massager (it's also suitable for virtually anywhere you can use a little extra TLC). Despite its simple interface, it boasts a whopping eight modes and 19 intensities. Thanks to a 15-minute auto shutoff feature, you can doze off while using it — worry-free.
Yoyomax Electric Foot Massager With Heat and Ice Therapy
Our experts agree the application of heat can do wonders for achy feet, but it can come at the risk of sores and infections, especially for users with diabetes. An alternate option with plenty of restorative benefits is this foot massager boasting a cold therapy component, proven to reduce inflammation and promote recovery.
Fit King Air Massager
This wraparound-style massager uses air compression to deliver a therapeutic massage from the knee all the way down, with two massage modes and three intensity levels. The attached handheld remote means, unlike the others hidden in your couch cushions, it'll never get lost. The massager comes with two calf extensions to fit a wider range of users. Personalized modes
When looking for an FSA-approved foot massager, 'it is best to first think about what you want the massager to do for you and your particular situation,' Nirenberg says. He recommends looking for foot massagers that allow you to alternate between massage types, like shiatsu, kneading and rolling, to suit your needs and comfort level. 'Features vary as well,' he says. 'Do you want vibration, heat or even a remote control if you do not want to have to bend down to operate the device? I know a lot of my older patients simply cannot bend down without difficulty, often due to arthritis, and for them, having a massager with a remote control [is a wise option].'
Alvarez says the foot massager should boast an ergonomic design that caters to different foot sizes so you can be sure it works for you. While FSA-approved foot massagers can indeed be therapeutic from a medical vantage point, he says they are also designed to be a useful tool for relaxation.
Wider massage ranges
According to Nirenberg, our calves play an important role in pumping blood throughout our feet and legs, so a massager that can assist in this function may be a worthy option. 'I try to find foot massagers that not only work on my feet but my calves as well,' Nirenberg says. 'These seem to get the blood moving better.'
Safety features
When heat and pressure are involved, you always want to look for safety features like auto shutoff. 'Another safety feature I like are massagers that can be set to turn off after a period of time automatically,' Nirenberg says. 'This way, if a person falls asleep, the machine will not keep going and lead to an injury.'
FSA eligibility
It may sound obvious, but it's worth the reminder: Before adding to cart, double-check that the foot massager in question is actually eligible for FSA reimbursement. 'Ensure the massager is explicitly labeled as FSA eligible and check the manufacturer's details, or consult your FSA plan administrator for confirmation,' Alvarez says.
Expert consultation
Before investing in an FSA-approved foot massager, speak with your medical provider or podiatrist to confirm whether the device is right for you. 'As an important caution for diabetic patients, those with neuropathy or poor circulation should check with their podiatrist first,' says Nirenberg, adding that some massagers can be quite strong or get very warm, posing a risk of developing sores or infections. 'Over my 30-plus years in practice, I have seen some diabetic patients end up with serious infections and even amputations from heating or massage devices.'
The following FAQs have been answered by podiatrist Gregory Alvarez.
What are the different types of FSA-approved foot massagers?
What are the different types of FSA-approved foot massagers?
FSA-approved foot massagers typically fall into the following categories.
Manual massagers, which are handheld or roller devices that provide customizable pressure.
Electric massagers, which are powered devices with features like vibration, kneading and heat therapy for deeper relaxation and therapeutic benefits.
Compression massagers, which use air pressure to improve circulation and reduce swelling, and is particularly beneficial for those with conditions like edema.
Hydrotherapy massagers, which are foot spas that combine water jets and massage functions for added relief.How do I use FSA dollars on an FSA-approved foot massager?
How do I use FSA dollars on an FSA-approved foot massager?
To use FSA dollars, purchase a foot massager labeled as FSA eligible through a retailer that accepts FSA cards or provides an itemized receipt for reimbursement. Some massagers may require a letter of medical necessity (LMN) from your health care provider, so check with your FSA plan to confirm any additional documentation requirements.
Are FSA-approved foot massagers similar in quality to regular foot massagers?
Are FSA-approved foot massagers similar in quality to regular foot massagers?
FSA-approved foot massagers are often the same quality as regular foot massagers. The key difference lies in their eligibility for FSA spending, which requires the device to meet specific health-related criteria. Many high-quality brands design products that qualify for FSA approval, ensuring you get both therapeutic benefits and value.
For this article, we consulted the following experts to gain their professional insights.
Dr. Gregory Alvarez, podiatrist at Ankle & Foot Centers of America
Dr. Michael Nirenberg, clinical and forensic podiatrist at Friendly Footcare in Indiana CNN Underscored thoroughly tests all the products we cover and provides full transparency about how we test them. We have an experienced team of writers and editors who have many years of testing experience and ensure each article is carefully edited and products are properly vetted. Contributing editor Marissa Miller has 15 years of experience writing and reporting on all things health and well-being, and serves as a certified personal trainer with a specialization in orthopedic exercise. For this article, she consulted two board-certified podiatrists for their advice on selecting the best FSA-approved foot massagers.
Explore trending products
HigherDose Full-Spectrum Infrared Sauna
Sunlighten mPulse Aspire Smart
Tatdol Portable Home Steam Sauna Box
Maxxus Lifesauna Aspen 2-Person Infrared
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections DUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the U.S. commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets. The Food and Drug Administration (FDA) approved ORLYNVAH™ for adult women with uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis with limited or no alternative oral antibacterial options in October 2024. ORLYNVAH™ is the first oral penem antibiotic commercially available in the U.S. and the first new branded product to be introduced in the U.S. for uUTI in more than 25 years – offering a critical option for patients and physicians facing a shrinking arsenal of effective oral therapies. Sixty percent of women experience a urinary tract infection in their lifetime and 44% experience three or more episodes annually. It is the most common outpatient infection in women in the United States, and resistance continues to increase. According to a 2024 U.S. study in approximately 150,000 patients with uncomplicated UTIs: 57% of initial infections were resistant to at least one antibiotic class; and 13% were resistant to three or more. Without new, safe and effective oral therapies, resistant uUTIs are expected to inflate healthcare costs and may lead to poor patient outcomes in the U.S., including the need for additional courses of therapy, emergency room visits or hospitalizations, all of which underscore the urgent need for innovation in this space. 'The availability of ORLYNVAH™ is tremendous news for clinicians and patients alike,' said Marjorie Golden, MD, FIDSA, Site Chief, Infectious Disease, St. Raphael Campus Yale New Haven Hospital. 'The launch of ORLYNVAH™ provides a new treatment option with impressive efficacy data to treat appropriate adult women suffering from difficult-to-treat uUTIs.' Dr. Golden added, 'For patients who currently have limited treatment options, ORLYNVAH™ provides a long overdue oral alternative that allows for treatment in the community. This paradigm shift in the management of patients with uUTI will not only reduce emergency department visits and hospital admissions, but it will also favorably impact patients' quality of life.' 'Our mission is to create new antibiotics for patients and to be a treatment alternative to address substantial unmet medical needs in the community,' said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. 'For many people with multidrug-resistant uUTIs, options have been exhausted. We're proud to introduce ORLYNVAH™—the first oral penem ever approved by the FDA—giving clinicians and patients a much-needed new therapy.' To support patient access, Iterum Therapeutics is launching a copay savings program allowing eligible patients to obtain ORLYNVAH™ for as little as $25. For more information about ORLYNVAH™, including full prescribing information, please visit Uncomplicated urinary tract infections (uUTIs) are a common bladder infection typically confined to the lower urinary tract in otherwise healthy women with no structural abnormalities of the urinary tract—caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis. About Iterum Therapeutics plcIterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug-resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received U.S. Food and Drug Administration approval for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options, and ORLYNVAH™ is commercially available in the United States. Iterum has also been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit About ORLYNVAH™ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode ESBL or AmpC-type ß-lactamases that confer resistance to third generation cephalosporins. Cautionary Note Regarding Forward-looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum's plans, strategies and prospects for its business, including the development, therapeutic and market potential of ORLYNVAH™ and the success of Iterum's commercialization of ORLYNVAH™ in the U.S. In some cases, forward-looking statements can be identified by words such as 'may,' 'believes,' 'intends,' 'seeks,' 'anticipates,' 'plans,' 'estimates,' 'expects,' 'should,' 'assumes,' 'continues,' 'could,' 'would,' 'will,' 'future,' 'potential' or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum's control, including Iterum's successful commercialization of ORLYNVAH™ in the U.S. with its commercial partner, EVERSANA, including Iterum's ability to maintain and continue to build a sales force for the commercialization of ORLYNVAH™ in the U.S., the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if the commercialization of ORLYNVAH™ in the U.S. is unsuccessful, the market opportunity for and the potential market acceptance of ORLYNVAH™ for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, the potential impact of resistant uUTIs on healthcare costs and medical outcomes for uUTI patients in the U.S., Iterum's ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum's expectations regarding how far into the future Iterum's cash on hand will fund Iterum's ongoing operations, Iterum's ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption 'Risk Factors' in its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2025, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum's beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. PRESS CONTACTJennifer PerciballiOak+Cannon PR for Iterumjennifer@ Investor RelationsJudy MatthewsChief Financial Officer Iterum Therapeutics 312-778-6073IR@
Yahoo
3 hours ago
- Yahoo
In Maryland, there's now a greener way to handle dead bodies
In Maryland, there's now a greener way to handle dead bodies Inside a white brick building in West Baltimore, a long silver chamber full of water seesawed back and forth over a platform. Within it, a body dissolved. Skin, flesh and organs turned into amino acids and sugars with each tip of the chamber. In a matter of hours, all that remained were bones and the leftover watery solution. Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. This process, which is called alkaline hydrolysis, but is known more colloquially as water cremation, has been gaining popularity across the country since it was first used in the funeral industry in 2011, according to the Cremation Association of North America. More than half the states in the U.S. have legalized the process, according to the association. Maryland joined the list last spring. Soon after, the Joseph H. Brown Jr. Funeral Home started offering the service. The Maryland Health Department said Brown's is the only funeral home it is aware of that offers the service in the state. The water cremations take place inside a back room of Brown's funeral home. The silver chamber sits beside a few large blue tubs filled with chemicals and a sequence of pipes snaking between the pieces of equipment. White printed labels with percentage signs and hazardous material markings cover the barrels of solution. The saline smell of a soapy chemical compound permeates the air as does the mechanical sound of steel scraping against itself in perfect intervals. The area looks like a tiny, makeshift chemical plant. But that's not what Arnecia Edwards saw in her mind when she thought of the procedure. She envisioned her father, John Edwards, who died at 88, gently laid into a pool at a spa and calmly rocking into the ether. She thought of him returning to one of the places he loved the most, where he spent some of the sweetest moments of his youth - the waterfront. She recalled him as a younger, healthier man, before a career on the railroad wore on his body, before the non-Hodgkin lymphoma invaded his white blood cells, the stroke tore through his brain and the diabetes through his body. She saw him standing at the water's edge at Patapsco Valley State Park soaking in the nature around him. She remembered him teaching her to swim. That's part of what led her to choose water cremation. 'I think he would have loved it,' Edwards said. Death care professionals say water cremation appeals to those who resonate with the idea of themselves or their loved ones departing the Earth through water. 'It's just a gentler process,' said Lily Buerkle, a licensed mortician based in D.C. It also attracts people looking for a greener alternative to fire cremation. Maryland's path to legalizing alkaline hydrolysis began, in part, when Adrian Gardner, a former lawyer for The Maryland-National Capital Park and Planning Commission, was grappling with his mother entering hospice about three years ago and started researching the death industry. He learned about 'green death,' a term for more environmentally-friendly methods of managing dead bodies, including alkaline hydrolysis and natural organic reduction, also known as human composting. That process involves enclosing the body in a capsule and heating it to speed up the body's natural decomposition process. Once complete, the body becomes a mound of soil that the family can sprinkle in their yard, pot a plant with or donate for environmental restoration projects. Gardner reached out to Buerkle, who was knowledgeable and outspoken about green death. They planned to open a funeral home together in Montgomery County offering both alkaline hydrolysis and natural organic reduction, but discovered neither was yet legal in Maryland, they said. They lobbied their lawmakers to change that. A bill legalizing alkaline hydrolysis and natural organic reduction passed in the Maryland legislature in 2024, and was signed into law by Gov. Wes Moore (D) that spring. 'We just want all the options on the table,' Buerkle said. The next step was for the state to draw up regulations for both methods. Joseph Brown didn't want to wait that long. The owner of the Joseph H. Brown Jr. Funeral Home had been eyeing alkaline hydrolysis for decades, and even redesigned his funeral home around the early 2000s with drains strategically placed in the facility for a future alkaline hydrolysis operation. 'I'm impatient,' Brown said. 'I'm a businessman.' Brown had faith that, over time, the industry would become a popular one in Maryland. The idea touches something within a grieving person, he explained. The use of water gives it more of a natural and spiritual feeling for some people than fire, he said. 'If you look at it biblically, we talk about our bodies as being earthen vessels. Earthen. Clay,' Brown said. 'We wash away the clay, the vessel, and we give the family back the minerals, the calcium and phosphate.' The gentle nature of the procedure can be particularly meaningful for those who've lost young ones, Buerkle added. It's almost like returning them to the amniotic sack, the liquid-filled pouch that surrounds a fetus during pregnancy, she explained. 'Especially people who've lost children, especially babies, they think about, in the womb, they really only knew water,' Buerkle said. But before Brown could start offering this service, there were logistical obstacles to consider. The resulting liquid from the process would need to go down the sewer. He met with the Baltimore's Department of Public Works about how to manage the discharge. Pat Boyle, a pollution control program administrator at the department, explained that a basic solution is used to dissolve the bodies. The solution is high on the pH scale, which means it could corrode the pipes. Brown would need to include an acidic additive into the solution to ensure the pipes would be protected. Once the discharge made its way to through the pipes, the wastewater treatment plant would take care of the filtration and send it back out into the lakes and rivers. The department gave Brown a permit, the legislature passed the law in 2024 and he got down to business, charging about $4,500 for each alkaline hydrolysis procedure. Brown was aware the state hadn't yet written regulations for alkaline hydrolysis, he said, and that put the process in a legal gray area. Brown said he kept in contact with relevant state and local officials and felt pioneering a new industry in the state would be worth potential consequences from regulators. 'The first gets the oyster and the pearl and makes the decision as to what to do with the shell,' Brown said. More than a year later, the regulations are still not finalized. Maryland's Office of Cemetery Oversight held a public meeting in June to fine-tune the proposed regulations and is still reviewing them. Brown estimates he's done about 30 water cremations since he started offering alkaline hydrolysis in the summer of 2024. For some, the concept of water cremation is so meaningful, they'll send a loved one's body across state lines to put them to rest. When Janet Jackson, of the San Antonio area, lost her six-month-old grandson in February, she said her son couldn't stomach the idea of lighting his baby's tiny body on fire or putting it in the ground. Jackson had heard of water cremation and told her son about it. 'Grayson loved his bubble baths so much,' Jackson said. 'Every night they would FaceTime me during bubble baths.' Water cremation felt like the closest thing to sending Grayson off in a bubble bath, Jackson said. But it wasn't legal in Texas. So they sent his body to Missouri where it was legal. Thinking of Grayson leaving his life in water felt like a way to infuse some of his individuality into his death, Jackson said. And she believes it's what Grayson would have wanted too. 'I hear him telling me 'thank you' all the time,' she said. Related Content In Donbas, Ukrainians hold out as Russia besieges, bargains for their land As more National Guard units arrive in D.C., local officials question the need Ukraine scrambles to roll back Russian eastern advance as summit takes place Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
Hologic HOLX is a leading name in the cytology space, with its Cytology business, part of its Diagnostics franchise, primarily focusing on screening for cervical cancer. The company has pioneered the first FDA-approved liquid-based cytology test — the ThinPrep Pap test — and the first FDA-approved mRNA-based HPV test — the Aptima HPV Assay. Co-testing — combining a Pap test with an HPV test — is the most sensitive testing option for cervical cancer screening compared to either test used alone. While this business of Hologic has historically been a flattish to single-digit grower, the company has continued to invest in it, like the 2024 launch of the Genius digital cytology system. It was a significant introduction, marking the only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. HOLX management noted that if not for the sales headwinds in China, Cytology would have grown in low single digits in the second quarter of fiscal 2025, driven by the rollout of its Genius digital diagnostics system, instead of reporting a 2.2% decline. With more labs around the world implementing this in-house innovation, Hologic has received strong positive feedback. Genius replaces the traditional manual review of path slides, which was previously conducted on glass under a microscope, by capturing a digital image of the slide, which can be reviewed remotely from anywhere in the customer's network on the company's review station. These workflow advantages not only address their growing labor shortages but also enable cervical cancer screening in regions with limited infrastructure. Because the Genius system requires an overhaul of the traditional pet screening workflow, Hologic expects the full rollout to be a multi-year process, serving as a growth driver for the next several quarters. HOLX's Peers in Cervical Cancer Screening Quest Diagnostics DGX offers a complete menu of solutions for screening and diagnosing cervical cancer. In April this year, DGX introduced a new solution aimed at expanding access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer. With this new offering, physicians can offer patients the option to collect their specimen for HPV screening in a physician's office or other healthcare setting. Quest Diagnostics' latest test uses the FDA-cleared HPV self-collection solution from Roche, approved for use with Roche Holding AG's RHHBY cobas HPV test in May 2024. Roche's cervical cancer portfolio includes three clinically validated tests to help identify women at risk and improve the detection of high-grade disease in a single round of screening. The cobas HPV test is the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for all cervical screening indications — primary screening, ASC-US triage and co-testing. The CINtec PLUS Cytology test is the only FDA-approved triage test that uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. Roche's CINtec Histology test uses advanced p16 biomarker technology to confirm cervical lesions due to transforming HPV infections. HOLX Stock Performance, Valuation and Estimates In the past six months, Hologic shares have risen 5.2% against the industry's 11.9% fall. Image Source: Zacks Investment Research Hologic is trading at a forward three-year price-to-earnings of 15.23X, lower than the industry average of 28.67X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research Consensus estimates for Hologic's fiscal 2025 earnings are showing a mixed trend. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research